Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
43 hedge funds and large institutions have $50.5M invested in Merrimack Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 7 closing their positions.
1% more capital invested
Capital invested by funds: $50M → $50.5M (+$484K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 45 → 43 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
88% less call options, than puts
Call options by funds: $38K | Put options by funds: $317K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.38M |
| 3 |
State Street
Boston,
Massachusetts
|
+$233K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$228K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$88.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.02M |
| 2 |
Two Sigma Advisers
New York
|
-$766K |
| 3 |
Renaissance Technologies
New York
|
-$569K |
| 4 |
BlackRock
New York
|
-$452K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$426K |
MACK Hedge Fund Activity: Q2 2021 in Review
43 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2021, worth a combined $50.5M — up 0.97% from $50M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MACK and 5 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was Western Standard LLC, adding an estimated $1.7M. The largest seller was Two Sigma Investments, cutting an estimated $1.02M.
- 43 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2021, down from 45 in Q1 2021.
- Funds reported $50.5M of Merrimack Pharmaceuticals, Inc. stock for Q2 2021, up 0.97% quarter-over-quarter.
- 5 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2021 and 7 closed out, a net change of -2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2021 was Western Standard LLC, an estimated $1.7M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2021 was Two Sigma Investments, an estimated $1.02M sold.
Based on aggregated 13F filings for Q2 2021.